Pharmact Healthcare

Pharmact is a healthcare group centered on Pharmact Holding AG in Baar, Switzerland, with subsidiaries involved in biotechnology, pharmaceutical development, and earlier in-vitro diagnostics activities. The company’s current strategic focus appears to be BELACT, a preclinical drug-development program built around its proprietary biotechnologically engineered enzyme D016 for arteriosclerosis, familial hypercholesterolaemia, and potentially other cardiovascular and neurodegenerative indications. Pharmact states that the enzyme is protected by patents and that production, regulatory development, and commercialization are handled through subsidiaries including Pharmact Pharmaceuticals GmbH in Germany. Historically, Pharmact Healthcare Inc. also marketed and distributed rapid COVID-19 diagnostic tests, indicating a broader medtech/diagnostics footprint in the group. Overall, Pharmact looks like a small private life-science group transitioning from diagnostics activity toward an enzyme-based therapeutic platform.